– Interview with Charles Craig, President of Georgia Bio; Stephen Hill, President, Solvay Pharmaceuticals, Inc.; and Russell Medford, M.D., Ph.D., President and CEO, Atherogenics, Inc.

Previous articleTransforming Bioprocessing as We Know It
Next articleChemDiv Purchases Prudentas to Strengthen Foothold in Eastern Europe